Dexamphetamine—a restricted stimulant drug used to treat narcolepsy and Attention Deficient Hyperactivity Disorder ...

Wake up and go to sleep The irony of these two narcolepsy drugs that work to normalise the sleep-wake cycle is that they have to be taken twice per night. Patients have the first dose before they ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline make it a strong buy for 2025.

The substance tested contained methamphetamines and theophylline, which are components found in the Captagon drug that Hamas ...

Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show. The Dublin-based company anticipates ...

Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Get Pro-Level Earnings Insights Before the Market ...

“People with narcolepsy, the drugs they’ve been using to treat their condition have basically been blunt instruments,” Pops said of the current array of stimulants and sedatives that treat ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.

A leading sleep expert highlighted the drug's transformative potential across narcolepsy subtypes and idiopathic hypersomnia (IH), suggesting it could significantly improve wakefulness compared to ...

DUBLIN - Avadel Pharmaceuticals plc (NASDAQ: NASDAQ:AVDL), a company specializing in the development of transformative medicines with a market capitalization of $1.05 billion, has announced ...